From: How does lymph node yield affect survival outcomes of stage I and II colon cancer?
Total | LN<12 | LN12-19 | LN≥20 | p | |
---|---|---|---|---|---|
N = 659 | N = 227 | N = 268 | N = 164 | ||
Age at surgery | 71.8 ± 12.1 | 72.1 ± 11.46 | 73.42 ± 11.14 | 68.51 ± 13.81 | < 0.001 |
Gender | |||||
Male | 363 (55.1%) | 132 (58.1%) | 155(57.89%) | 76(46.3%) | 0.034 |
Female | 296 (44.9%) | 95(41.9%) | 113(42.2%) | 88 (53.7%) | |
ASA | |||||
1–2 | 431 (65.4%) | 144(66.1) | 166(63.6) | 121(80.1) | 0.002 |
≥ 3 | 199 (30.2%) | 74(33.9) | 95(36.4%) | 30(19.9%) | |
CCI | 2.47 ± 0.8 | 2.4 ± 0.8 | 2.6 ± 0.8 | 2.4 ± 0.7 | 0.105 |
Preoperative CEA | 12.5 ± 40.6 | 8.7 ± 30.6 | 13.1 ± 39.1 | 16.7 ± 53.3 | 0.245 |
Year of surgery | |||||
2003–2007 | 329 (49.9%) | 151 (66.5%) | 110 (41.0%) | 68 (41.5%) | < 0.001 |
2008–2012 | 330 (50.1%) | 76 (33.5%) | 158 (59.0%) | 96 (58.5%) | |
Type of surgery | |||||
Elective | 555 (84.2%) | 187 (82.4%) | 231 (86.2%) | 137 (83.5%) | 0.491 |
Emergency | 104 (15.8%) | 40 (17.6%) | 37 (13.8%) | 27 (16.5%) | |
Surgical approach | |||||
Laparoscopic | 304 (46.1%) | 90 (39.8%) | 137 (51.3%) | 77 (47.0%) | 0.011 |
Open | 335 (50.8%) | 134 (59.3%) | 121(45.3%) | 80 (48.8%) | |
Laparoscopic converted open | 18 (2.7%) | 2 (0.9%) | 9 (3.4%) | 7 (4.3%) | |
Site of tumour | |||||
Caecum | 72 (10.9%) | 24 (10.6%) | 31 (11.6%) | 17 (10.4%) | 0.914 |
Ascending colon | 97 (14.7%) | 28 (12.3%) | 45 (16.8%) | 24 (14.6%) | |
Hepatic flexure | 63 (9.6%) | 17 (7.5%) | 27 (10.1%) | 19 (11.6%) | |
Transverse colon | 93 (14.1%) | 33 (14.5%) | 37 (13.8%) | 23 (14.0%) | |
Splenic flexure | 31 (4.7%) | 10 (4.4%) | 11 (4.1%) | 10 (6.1%) | |
Descending colon | 67 (10.2%) | 28 (12.3%) | 26 (9.7%) | 13 (7.9%) | |
Sigmoid colon | 236 (35.8%) | 87 (38.3%) | 91 (33.9%) | 7 (35.3%) | |
Type of resection | |||||
Right sided | 323 (49.0%) | 99 (43.6) | 139 (51.9%) | 85 (51.8%) | 0.159 |
Left sided | 306 (46.4%) | 120 (52.9%) | 117 (43.7%) | 69 (42.1%) | |
Subtotal | 30 (4.6%) | 8 (3.5%) | 12 (4.5%) | 10 (6.1%) | |
Perforation | |||||
Yes | 29 (4.4%) | 10(4.4%) | 13(4.9%) | 6(3.7%) | 0.842 |
No | 630 (95.6%) | 217(95.6%) | 255(95.1%) | 158(96.3%) | |
Obstruction | |||||
Yes | 114 (17.3%) | 37(16.4%) | 44(16.4%) | 33 (20.2%) | 0.531 |
No | 543 (82.4%) | 189(83.6%) | 224(83.6%) | 130(79.8%) | |
Tumour size | 42.1 ± 26.6 | 37.1 ± 21.9 | 42.6 ± 27.5 | 48.0 ± 29.7 | < 0.001 |
T stage | |||||
1&2 | 155 (23.6%) | 68 (30.0%) | 61 (22.8%) | 26 (15.9%) | 0.005 |
3&4 | 503 (76.4%) | 159 (70.0%) | 206 (77.2%) | 138 (84.1%) | |
Differentiation | |||||
Well | 58 (8.8%) | 24 (11.3%) | 24 (9.2%) | 10 (6.2%) | 0.563 |
Moderate | 533 (80.9%) | 176 (83.0%) | 216 (83.1%) | 141 (87.6%) | |
Poor | 39 (5.9%) | 11 (5.2%) | 19 (7.3%) | 9 (5.6%) | |
Perineural invasion | |||||
Yes | 40 (6.1%) | 15 (6.8%) | 15 (5.7%) | 10 (6.1%) | 0.888 |
No | 604 (91.7%) | 205 (93.2%) | 246 (94.3%) | 153 (93.9%) | |
LVP | |||||
Yes | 92 (14.0%) | 39 (17.3%) | 39 (14.8%) | 14 (8.6%) | 0.049 |
No | 559 (84.8%) | 186 (82.7%) | 225 (85.2%) | 148 (91.4%) | |
Mucinous | |||||
Yes | 63 (9.6%) | 16(7.2%) | 31 (11.7%) | 16 (10.0%) | 0.383 |
No | 583 (88.5%) | 205 (92.8%) | 234 (88.0%) | 144 (90.0%) | |
Signet | |||||
Yes | 2 (0.3%) | 221 (100%) | 263 (99.2%) | 160 (100.0%) | 0.236 |
No | 644 (97.7%) | 0 (0%) | 2 (0.8%) | 0 (0%) | |
Margin | |||||
Involved | 1 (0.4%) | 0 (0.0%) | 1 (0.6%) | 2 (0.3%) | 0.481 |
Clear | 226 (99.6%) | 268 (100.0%) | 163 (99.4%) | 657 (99.7%) | |
Adjuvant chemotherapy | |||||
Yes | 36 (15.9%) | 35 (13.1%) | 35 (21.3%) | 106 (16.1%) | 0.075 |
No | 191 (84.1%) | 233 (86.9%) | 129 (78.7%) | 553 (83.9%) |